Merck Reaches Agreement With U.S. Government to Expand Access to Medicines and Lower Costs for Americans

Merck struck an agreement with the U.S. government that includes a direct-to-patient program offering JANUVIA, JANUMET and JANUMET XR to eligible Americans at roughly 70% off current list prices and a commitment to offer the oral PCSK9 candidate enlicitide at an affordable price if approved. The company secured a three-year delay of Section 232 tariffs with the Department of Commerce to support reshoring and announced over $70 billion in planned U.S. capital and R&D spending (including at least $12 billion in capex), building on $12 billion in manufacturing investment since 2017 and $81 billion in U.S. R&D since 2018. The deal and investment plan aim to expand domestic manufacturing, lower patient costs and could influence Merck’s future revenue mix and cost structure while reducing trade-related uncertainties.

Analysis

Market structure: Merck (MRK) is the clear direct beneficiary — near-term volume upside for sitagliptin portfolio and optionality from oral PCSK9 (enlicitide) can expand addressable market versus injectable PCSK9s (AMGN, REGN). Payers and PBMs are short-term winners (lower cash prices), while incumbent injectable specialists face pricing and penetration pressure; expect 3–8% share migration in preventive cardiovascular prescriptions over 12–24 months if enlicitide gains approval and uptake. The three-year Section 232 delay reduces near-term input-cost/tariff risk and supports capital spending, which should modestly improve long-term gross-margin visibility.

Risk assessment: Tail risks include FDA rejection of enlicitide (low-probability, high-impact), expedited political moves to broader price controls (medium risk over 1–3 years), and operational execution risk from $70B capex (construction/permits, 12–36 months). Immediate market reaction will be driven in days; short-term (weeks–months) by regulatory milestones and Q/Q guidance; long-term (years) by realized manufacturing cost savings and volume ramp. Hidden dependencies: the discount program’s eligibility and payer reimbursement mechanics determine real revenue impact — a 70% list-price cut may translate to <25% net revenue decline for affected scripts depending on who pays.

Trade implications: Favor a modest constructive posture on MRK but hedge execution and regulatory risk: establish 2–3% long MRK equity weight with a 10% stop and 12-month target +15–25% if enlicitide clears FDA or guidance improves. Implement a relative-value pair: long MRK (2%) / short AMGN (1.5%) to express oral PCSK9 disruption over 6–12 months. Use options to limit capital: buy a 12-month MRK call spread (buy ATM, sell 20% OTM) sized 0.5–1% of portfolio to capture upside while capping cost; consider buying short-dated put protection if share drops >8% on earnings.

Contrarian angles: Consensus underestimates the upside from reshoring — if capex reduces COGS by 100–200bps over 3–5 years, EPS accretion could be 5–10% above current consensus, making MRK underowned. Conversely, market may be underpricing regulatory precedent risk: this voluntary deal could accelerate broader price concessions across Big Pharma, compressing sector margins by 100–300bps over 2–4 years. Watch historical parallels (voluntary pricing programs by large pharma) where volume gains offset <50% of price concessions; outcome will hinge on payer take-up and enlicitide’s real-world effectiveness.

Key Decisions for Investors

• Establish a 2–3% long position in MRK (equity) within 1–2 weeks, target +15–25% over 12 months; set a 10% stop-loss and reduce to 0.5–1% if company reports >150bps gross-margin contraction in next two quarters.
• Put on a pair trade: Long MRK 2% / Short AMGN 1.5% (equal-dollar basis) to express oral-PCSK9 optionality; horizon 6–12 months, close or rebalance on an FDA decision for enlicitide or if AMGN announces a competing oral program.
• Buy a 12-month MRK call spread (buy ATM, sell 20% OTM) sized 0.5–1% of portfolio to capture upside while limiting premium; if enlicitide obtains FDA approval, roll up exposure and trim equity position to lock gains.
• If MRK credit spreads widen >25bps vs. IG peers, buy 3–5 year MRK corporate bonds (or CDS protection sold) to harvest spread compression; conversely, if spread compression is >30bps post-reshoring proof points, take profits within 6–18 months.